The settlement of the vaccine advance purchase agreement with Gavi removes a significant uncertainty and potential financial liability for Novavax. This resolution is likely to be viewed positively by investors, as it clears a path for smoother operations and financial planning for Novavax going forward. The immediate positive reaction in the stock price reflects investor relief and optimism about the company's ability to move past this challenge.